Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Sponsor: AJU Pharm Co., Ltd.
Summary
This study is planned to Evaluate the Efficacy and Safety of OM-89 in Patients with Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Official title: A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase 4 Study to Evaluate the Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Key Details
Gender
MALE
Age Range
19 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
332
Start Date
2023-12-20
Completion Date
2026-03-30
Last Updated
2024-04-04
Healthy Volunteers
No
Conditions
Interventions
OM-89 [Uro-Vaxom® Capsule]
Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day
OM-89 Placebo [Uro-Vaxom® Capsule Placebo]
Oral administration of the investigational product(Placebo of Uro-Vaxom® Capsule)
Locations (1)
AJU Pharm Co., Ltd.
Seoul, South Korea